The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer |
| |
| Institution: | 1. Department of Urology, Erasmus University Medical Center and Cancer Institute, Rotterdam, The Netherlands;2. Department of Medical Oncology, Erasmus University Medical Center and Cancer Institute, Rotterdam, The Netherlands;3. Department of Biostatistics, Erasmus University Medical Center and Cancer Institute, Rotterdam, The Netherlands;4. Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands;5. Department of Internal Medicine, Tweesteden Hospital, Tilburg, The Netherlands;6. Department of Internal Medicine, Reinier de Graaf Hospital, Delft, The Netherlands;7. Department of Clinical Trial Center, Erasmus University Medical Center and Cancer Institute, Rotterdam, The Netherlands;8. Department of Internal Medicine, St Franciscus Gasthuis and Prostate Cancer Center, Rotterdam, The Netherlands;1. Medical Oncology Department, Santa Chiara Hospital, Trento, Italy;2. Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;3. Medical Oncology Department, National Cancer Institute, Aviano, Italy;4. Department of Radiological, Oncological and Anatomopathological Sciences, La Sapienza, University of Rome, Rome, Italy;5. Medical Oncology Unit 1, Istituto Oncologico Veneto IOV - IRCCS, Padua, Italy;6. Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Naples, Italy;7. Medical Oncology Department, General Hospital, Parma, Italy;8. Medical Oncology I - Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy;9. Medical Oncology Department, University of Torino, San Luigi Hospital, Orbassano, Italy;10. Medical Oncology Department, Villa Sofia Cervello Hospital, Palermo, Italy;11. Medical Oncology Department, General Hospital, Lugo di Romagna, Italy;12. Medical Oncology Department, Santa Maria degli Angeli Hospital, Pordenone, Italy;13. Medical Oncology Department, Fondazione Istituto Nazionale Tumori, Milan, Italy;14. Medical Oncology Division, Azienda Ospedaliero Universitaria, Policlinico di Modena, Modena, Italy;15. Medical Oncology Department, General Hospital, Cremona, Italy;p. Medical Oncology Department, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy;q. Medical Oncology Department, General Hospital, Mirano, Italy;r. Department of Medical Oncology and Haematology, Humanitas Clinical and Research Center, Rozzano, Italy;s. Medical Oncology Department, General Hospital, Faenza, Italy;t. Medical Oncology Department, San Vincenzo Hospital, Taormina, Italy;u. Division of Medical Oncology, San Giacomo Hospital, Castelfranco Veneto, Italy;v. Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy;w. Medical Oncology Department, University Campus bio-Medico, Rome, Italy;x. Medical Oncology Department, General Hospital, Verona, Italy;y. Medical Oncology Department, Papa Giovanni XXIII Hospital, Bergamo, Italy;z. Medical Oncology Department, IRCCS Azienda Ospedaliera Universitaria San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy;11. Medical Oncology Department, General Hospital, Imola, Italy;22. Medical Oncology Department, Niguarda Cancer Centre, Ospedale Niguarda Ca’ Granda, Milan, Italy;33. Medical Oncology Department, Referral Cancer Centre of Basilicata-IRCCS, Rionero in Vulture, Italy;44. Medical Oncology Department, General Hospital, Carpi, Italy;55. Medical Oncology Department, Santa Maria della Misericordia University Hospital, Udine, Italy;1. Medical Oncology, S. Chiara Hospital, Largo Medaglie d’oro 1, 38122 Trento, Italy;2. Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Piazzale L.A. Scuro 10, 37134 Verona, Italy;1. Medical Oncology Department, Santa Chiara Hospital, Trento, Italy;2. Medical Oncology Department, Institute for Cancer Research and Treatment, Candiolo, Italy;3. Oncologia Urologica, Azienda Ospedaliera Universitaria \"Federico II\", Napoli, Italy;4. Medical Oncology Department, General Hospital, Verona, Italy;5. Medical Oncology Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)—IRCCS, Meldola, Italy;6. Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori “Fondazione G. Pascale”—IRCCS, Naples, Italy;7. Medical Oncology Department, Santa Maria della Misericordia Hospital, Udine, Italy;8. Medical Oncology Department, General Hospital, Merano, Italy;9. Medical Oncology Department, Referral Cancer Center of Basilicata—IRCCS, Rionero in Vulture, Italy;10. Medical Oncology Department, Papa Giovanni XXIII Hospital, Bergamo, Italy;11. Medical Oncology Department, San Luigi Hospital, University of Torino, Orbassano, Italy;12. Urology Department, General Hospital, Bolzano, Italy;13. Medical Oncology Department, General Hospital, Frosinone, Italy;14. Department of Medical Oncology and Haematology, Humanitas Clinical and Research Center, Rozzano, Milan, Italy;15. Department of Radiological, Oncological and Anatomopathological Sciences, La Sapienza, University of Rome, Rome, Italy;p. Medical Oncology Department, San Vincenzo Hospital, Taormina, Italy;q. Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy;r. Medical Oncology Department, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy;s. Oncologia medica genitourinaria—Fondazione Istituto Nazionale Tumori, Milan, Italy;t. Medical Oncology Department, University Campus Bio-Medico, Rome, Italy;u. Medical Oncology Department, National Cancer Institute, Aviano, Italy;v. Medical Oncology Department, Santa Maria degli Angeli Hospital, Pordenone, Italy;w. Medical Oncology Department, ULSS5 Ovest Vicentino, Montecchio Maggiore, Italy;x. Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV—IRCCS, Padua, Italy;y. Medical Oncology Department, San Giacomo Apostolo Hospital, Castelfranco Veneto, Italy;1. Department of Ambulatory Care, Gustave-Roussy Cancer Campus, University of Paris Sud, Villejuif, France;2. Department of Biostatistics and Epidemiology, Gustave-Roussy Cancer Campus, University of Paris Sud, Villejuif, France;3. Department of Cancer Medicine, Gustave-Roussy Cancer Campus, Villejuif, University of Paris Sud, France;1. Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, Sweden;2. Department of Translational Medicine, Centre of Medical Informatics, Lund University, Lund, Sweden;3. Department of Astronomy and Theoretical Physics, Lund University, Lund, Sweden;4. Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden;5. Department of Translational Medicine, Division of Urological Cancers, Malmö, Lund University, Lund, Sweden;6. Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden;7. Department of Urology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden;8. Department of Oncology, Norrland University Hospital, Umeå University, Umeå, Sweden;9. Department of Radiation Sciences, Umeå University, Umeå, Sweden;10. Martini-Klinik, Prostate Cancer Centre, Hamburg, Germany;11. Department of Urology, Hamburg University Hospital, Hamburg, Germany;12. Department of Urology, Skåne University Hospital, Malmö, Sweden |
| |
| Abstract: | IntroductionThe treatment armamentarium for metastatic castration-resistant prostate cancer (mCRPC) has expanded with the introduction of several new therapies. In this treatment continuum, it is unclear whether the efficacy of cabazitaxel is affected by prior novel androgen receptor targeted therapies (ART) such as abiraterone and enzalutamide. In this study, we investigated the influence of prior ART on the efficacy of cabazitaxel in men with mCRPC.Patients and methodsData from an ongoing multicentre, phase II trial were used comprising 114 men with mCRPC treated with cabazitaxel in the post-docetaxel setting. The primary endpoints of the current analysis were prostate-specific antigen (PSA) response (?50%), and overall survival (OS). Univariate and multivariable analyses were conducted to investigate the influence of prior ART on the efficacy of cabazitaxel.ResultsFrom the 114 patients included in this analysis, 44 men received prior ART and 70 men did not receive prior ART before treatment with cabazitaxel. PSA response rates while on cabazitaxel treatment were similar in patients with and without prior ART (34% versus 40%, respectively, P = 0.53). Likewise, median OS was not significantly different between men with and without prior ART (13.0 versus 14.0 months, respectively, logrank P = 0.65). In multivariable analysis, the only variables significantly associated with OS were performance status, serum albumin and alkaline phosphatase.ConclusionOur study showed that prior treatment with ART may not influence the efficacy of cabazitaxel in men with mCRPC. With emerging evidence of cross-resistance in the treatment of mCRPC, cabazitaxel provides a good treatment option irrespective of prior ART. |
| |
| Keywords: | Abiraterone Cabazitaxel Enzalutamide Metastatic castration-resistant prostate cancer Taxanes |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
